Literature DB >> 17682072

A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6.

Robert L Walsky1, R Scott Obach.   

Abstract

The use of selective chemical inhibitors of human cytochrome P450 (P450) enzymes represents a powerful method by which the relative contributions of various human P450 enzymes to the metabolism of drugs can be determined. However, the identification of CYP2B6 in the metabolism of drugs has been more challenging because of the lack of a well established inhibitor of this enzyme. In this report, we describe the selectivity of 2-phenyl-2-(1-piperidinyl)propane (PPP) as an inactivator of CYP2B6 and compare this selectivity versus other CYP2B6 inactivators: 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine. Values of K(I) and k(inact) for PPP were 5.6 microM and 0.13/min for bupropion hydroxylase catalyzed by pooled human liver microsomes, and values for thioTEPA were similar (4.8 microM and 0.20/min, respectively). Intrinsic inactivation capability was considerably greater for clopidogrel because of a greater k(inact) value (1.9/min). Ticlopidine was potent with K(I) and k(inact) values of 0.32 microM and 0.43/min, respectively. The selectivity of these four agents for CYP2B6 was determined by testing their effects on other human P450 enzyme activities using conditions that yield approximately 90% inactivation of CYP2B6 activity. The results showed that preincubation of human liver microsomes with PPP at 30 microM for 30 min provided more selective inhibition for CYP2B6 than thioTEPA, clopidogrel, and ticlopidine. Furthermore, the use of clopidogrel is complicated by the observation that this agent is not stable in the presence of human liver microsomes, even without addition of NADPH. Therefore, PPP can serve as a selective chemical inactivator of CYP2B6 and be used to define the role of CYP2B6 in the metabolism of drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17682072     DOI: 10.1124/dmd.107.015883

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

1.  Risk assessment of mechanism-based inactivation in drug-drug interactions.

Authors:  Yasushi Fujioka; Kent L Kunze; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2012-06-08       Impact factor: 3.922

2.  Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.

Authors:  Yan Chang; Wenfang B Fang; Shen-Nan Lin; David E Moody
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-09-02       Impact factor: 4.080

Review 3.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

4.  Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.

Authors:  Evan T Ogburn; David R Jones; Andrea R Masters; Cong Xu; Yingying Guo; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2010-03-24       Impact factor: 3.922

5.  Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism.

Authors:  Lindsay J Yanakakis; Namandjé N Bumpus
Journal:  Drug Metab Dispos       Date:  2012-01-23       Impact factor: 3.922

6.  Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme.

Authors:  Haoming Zhang; Hemali Amunugama; Sarah Ney; Nyemade Cooper; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2011-08-23       Impact factor: 4.436

7.  Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice.

Authors:  Jillissa C Molnari; Hazem E Hassan; Alan L Myers
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-09-17       Impact factor: 2.441

8.  Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.

Authors:  Jyothi C Talakad; Santosh Kumar; James R Halpert
Journal:  Drug Metab Dispos       Date:  2008-12-12       Impact factor: 3.922

Review 9.  CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.

Authors:  Hongbing Wang; Leslie M Tompkins
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

10.  Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison.

Authors:  Julie M Lade; Lindsay B Avery; Namandjé N Bumpus
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.